Xtant Medical reports record FY 2023 revenue $91.3M, up 58% YoY; guides FY 2024 $112M-$116M

Xtant Medical Holdings, Inc.

2024-Q1 EPS reported -$0.03 revenue$27,873,000

FY 2023 revenue $91.3M, +58% YoY; organic growth 15%.
Net income $0.7M ($0.01/share) vs net loss $8.5M ($0.09) in 2022.
Non-GAAP adjusted EBITDA $1.0M in 2023, compared to loss of $3.0M in 2022.
FY 2024 revenue guidance $112M-$116M, representing 23%-27% growth.
Gross margin improved 540 bps to 60.8% for 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.